Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Influenza Prevention Clear all
Completed Not applicable Interventional Results available

The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination

NCT01009645
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Fact Only Education Message, Fact and Myth Educational Message, Fact, Myth, Why Educational Message, Control Educational Message
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)

NCT00380237
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project to Investigate Ways to Reduce the Spread of Influenza in Schools and Households With Children

NCT00446628
View directory record Official record
Conditions
Influenza
Interventions
behaviors reducing spread of influenza
Behavioral
Lead sponsor
Kiren Mitruka
Federal
Eligibility
6 Months and older
Enrollment
3,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

NCT01855945
View directory record Official record
Conditions
Prophylaxis of A/H3N2v Influenza
Interventions
Swine Influenza
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
3 Years to 92 Years
Enrollment
627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
11
States / cities
Redding, California • Sacramento, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

NCT01175122
View directory record Official record
Conditions
Influenza A Virus Infection
Interventions
H2N3 MO 2003/AA ca Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 42 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine

NCT00734175
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H6N1 Teal HK 97/AA ca recombinant vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season

NCT03158038
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Monovalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

NCT06609460
View directory record Official record
Conditions
Influenza
Interventions
CD388 Injection, Placebo
Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 63 Years
Enrollment
5,071 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
56
States / cities
Anniston, Alabama • Cullman, Alabama • Tempe, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults

NCT00516035
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01859143
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

NCT03121339
View directory record Official record
Conditions
Seasonal Influenza Preventative Vaccine Pharmacodynamics
Interventions
VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large)
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

NCT01250795
View directory record Official record
Conditions
Healthy
Interventions
HAI-05 Influenza Vaccine, Saline
Biological · Other
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Wichita, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults

NCT01302990
View directory record Official record
Conditions
Flu
Interventions
Dose given at Day 0
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season

NCT02743117
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Monovalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Not applicable Interventional Results available

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

NCT02266277
View directory record Official record
Conditions
Influenza, Infections, Pneumococcal
Interventions
Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call, Arm 5: IVR call
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional

Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study

NCT00646152
View directory record Official record
Conditions
Influenza, Severe Acute Respiratory Distress Syndrome, Smallpox, Ebola, Unknown Respiratory Viruses
Interventions
Poly-ICLC
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

NCT02124161
View directory record Official record
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Interventions
13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe

NCT01644149
View directory record Official record
Conditions
Influenza Prophylaxis
Interventions
Stratis Jet Injector, Needle and Syringe, 2011-2012 Fluzone trivalent inactivated influenza vaccine
Device · Biological
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

NCT00722774
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H2N2 1960 AA ca recombinant vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2008 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

NCT05608005
View directory record Official record
Conditions
Influenza, Healthy Volunteers
Interventions
Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
16
States / cities
Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 4 Interventional Results available

A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants

NCT00412737
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 3, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

NCT01995695
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 3, 2026, 10:51 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

NCT02015494
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 40 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Lenexa, Kansas • Rochester, New York • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 3, 2026, 10:51 PM EDT